OFATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, DOXORUBICIN HYDROCHLORIDE, VINCRISTINE SULFATE, AND DEXAMETHASONE ALTERNATING WITH OFATUMUMAB IN COMBINATION WITH CYTARABINE AND METHOTREXATE IN TREATING PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: